Circulating tumor DNA assisting lymphoma genetic feature profiling and identification
Annals of Hematology · 2024
DOI: 10.1007/s00277-024-05782-0 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Hematology, 2024. Verfasst von Hongbiao Wang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology Session No.1, Cancer Hospital of Shantou University Medical College, Shantou, China. Hauptthemen laut MEDLINE: Circulating Tumor DNA, Lymphoma, Large B-Cell, Diffuse, Hodgkin Disease. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: Medical Science and Technology Foundation of Guangdong Province, National Natural Science Foundation of China, National Natural Science Foundation of Guangdong Province.
Abstract (Originalsprache)
INTRODUCTION: Lymphoma tissue biopsies cannot fully capture genetic features due to accessibility and heterogeneity. We aimed to assess the applicability of circulating tumor DNA (ctDNA) for genomic profiling and disease surveillance in classic Hodgkin lymphoma (cHL), primary mediastinal large B-cell lymphoma (PMBCL), and diffuse large B-cell lymphoma (DLBCL). METHODS: Tumor tissue and/or liquid biopsies of 49 cHLs, 32 PMBCLs, and 74 DLBCLs were subject to next-generation sequencing targeting 475 genes. The concordance of genetic aberrations in ctDNA and paired tissues was investigated, followed by elevating ctDNA-based mutational landscapes and the correlation between ctDNA dynamics and radiological response/progression. RESULTS: ctDNA exhibited high concordance with tissue samples in cHL (78%), PMBCL (84%), and DLBCL (78%). In cHL, more unique mutations were detected in ctDNA than in tissue biopsies (P < 0.01), with higher variant allele frequencies (P < 0.01). Distinct genomic features in cHL, PMBCL, and DLBCL, including STAT6, SOCS1, BTG2, and PIM1 alterations, could be captured by ctDNA alone. Prevalent PD-L1/PD-L2 amplifications were associated with more concomitant alterations in PMBCL (P < 0.01). Moreover, ctDNA fluctuation could reflect treatment responses and indicate relapse before imaging diagnosis. CONCLUSIONS: Lymphoma genomic profiling by ctDNA was concordant with that by tumor tissues. ctDNA might also be applied in lymphoma surveillance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical Oncology Session No.1, Cancer Hospital of Shantou University Medical College, Shantou, China.
- Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, 651 Dongfeng Road East, Guangzhou, 510060, Chin…
- Geneseeq Research Institute, Nanjing Geneseeq Technology Inc, Nanjing, China.
- Department of Hematology, Shunde Hospital, Southern Medical University (the First People's Hospital of Shunde Foshan), No.1 Jiazi Road, Licun, Lunjiao Street, Shunde District, Foshan, 528300, China. 741498893@qq.com.
Förderung
- Medical Science and Technology Foundation of Guangdong Province
- National Natural Science Foundation of China
- National Natural Science Foundation of Guangdong Province
- Lymphoma Research Fund of China Anti-Cancer Association and the Sun Yat-sen University Cancer Center Clinical Research 308 Program
Zitieren
APA
Wang, H., Wang, Z., Zhu, S., Li, Z., Yang, H., Sun, P., Zhu, M., Zhao, X., Shen, L., Ou, Q., Yang, H., & Li, Z. M. (2024). Circulating tumor DNA assisting lymphoma genetic feature profiling and identification. Annals of Hematology. https://doi.org/10.1007/s00277-024-05782-0
Vancouver
Wang H, Wang Z, Zhu S, Li Z, Yang H, Sun P, et al. Circulating tumor DNA assisting lymphoma genetic feature profiling and identification. Annals of Hematology. 2024. doi:10.1007/s00277-024-05782-0
BibTeX
@article{Wang2024,
author = {Wang, Hongbiao and Wang, Zhao and Zhu, Sujuan and Li, Zhifeng and Yang, Hang and Sun, Peng and Zhu, Minyi and Zhao, Xiaotian and Shen, Lu and Ou, Qiuxiang and Yang, Hui and Li, Zhi-Ming},
title = {Circulating tumor DNA assisting lymphoma genetic feature profiling and identification},
journal = {Annals of Hematology},
year = {2024},
doi = {10.1007/s00277-024-05782-0}
}
EUVIMED